C4 Therapeutics adds Dr. Laura Bessen and Dr. Donna Grogan to its Board of Directors

– USA, MA –  C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical company today announced the appointments of Dr. Laura Bessen (M.D.) and Dr. Donna Grogan (M.D.) to its Board of Directors.

“We are delighted to announce Laura and Donna as C4T’s newest directors after an extensive search that included a talented and diverse pool of clinical development leaders experienced in helping companies bring innovative therapies to patients,” said Board Chairman, Bruce Downey. “On behalf of the board of directors, I look forward to working closely with Laura and Donna as C4T continues to evolve in our pursuit of delivering on the potential of targeted protein degradation science to create a new generation of medicines and change how diseases are treated.”

About Dr. Laura Bessen

Dr. Laura Bessen currently serves as managing partner at Maxsam Advisors LLC where she provides strategic clinical and medical affairs advice to clients across the biotechnology and pharmaceutical industries. Previously, she held roles of increasing responsibility over a 15-year career at Bristol Myers Squibb, most recently as VP, and Head of US Medical. During her tenure at BMS, she helped launch 11 new products including Opdivo, Yervoy, elotuzumab, and Eliquis, and co-led BMS’ partnership with Gilead to develop Atripla. Dr. Bessen also co-led the development of the BMS product commercialization model, life cycle management, and launch investment principles. Earlier in her career, Dr. Bessen served in medical affairs roles at DuPont Pharmaceuticals. She currently serves on the Board of Directors of Artiva Biotherapeutics, an oncology company developing and advancing off-the-shelf, allogeneic natural killer cell therapies for patients with hematologic cancers or solid tumors.

“I am eager to use my broad experiences in medical affairs and clinical development to help C4T advance multiple oncology programs to benefit patients,” said Dr. Laura Bessen. “C4T is at a transformational stage, with two programs in the clinic and additional programs preparing to advance into clinical trials. I am excited to help C4T capitalize upon opportunities ahead.”

Dr. Bessen received her M.D. degree from New York University School of Medicine and B.S. in biochemistry from the State University of New York at Binghamton.

About Donna Grogan, M.D.

Donna Grogan, M.D. currently serves as Principal of Grogan Consulting LLC where she supports clients across drug development, regulatory strategy, trial design, and data interpretation. Between September 2013 and June 2019, Dr. Grogan served as CMO of Clementia Pharmaceuticals, which was acquired by Ipsen in April 2019. She previously served as CMO for several HealthCare Ventures portfolio companies including Anexon, Apofore, and DecImmune. Between February 2007 and August 2011, Dr. Grogan served as CMO, and SVP of Clinical Development at FoldRx Pharmaceuticals, which was acquired by Pfizer in October 2010. Earlier in her career, she held roles of increasing responsibility at Sepracor, Inc. where she was involved in multiple high-profile product approvals including Lunesta, Xopenex HFA, and Brovana. Dr. Grogan previously served as a board member, including membership on the Compensation Committee and the Scientific Committee, of Momenta Pharmaceuticals until it was acquired by J&J in October 2020.

Dr. Donna Grogan said, “It is an exciting time to join C4T and partner with the company to navigate drug development and regulatory milestones to advance an innovative portfolio of small-molecule medicines. I look forward to working with my C4T colleagues to help the Company apply its industry-leading targeted protein degradation science to transform how patients are treated.”

She holds an M.D. from the University of Illinois College of Medicine and a B.A. from the College of the Holy Cross.

About C4 Therapeutics

C4 Therapeutics is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transform patients’ lives. C4T is leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines that harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases.

For more information: https://c4therapeutics.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team